Canagliflozin / Metformin (Invokamet)
SGLT2 inhibitor and biguanide combination (antihyperglycemic)
Canagliflozin / Metformin (Invokamet)
Forms and strengths
Form: TabletStrength: 50 mg/500 mg, 50 mg/1000 mg, 150 mg/1000 mg
References
Indication
- Invokamet is used with diet and exercise to improve blood sugar control in adults with type 2 diabetes who are not adequately controlled on metformin alone or in combination with other diabetes medications such as a sulfonylurea, pioglitazone, or insulin.
- It may also be used in patients already achieving control on separate canagliflozin and metformin tablets, as a switch to the combined product.
- Invokamet is not indicated for type 1 diabetes or for treating diabetic ketoacidosis.
Pregnancy
Contraindicated in pregnancy. Confirm pregnancy status and discuss alternative therapy with the prescriber before dispensing.
- Invokamet is contraindicated during pregnancy.
- There are no adequate studies of Invokamet or its individual components in pregnant women.
- Canagliflozin may affect kidney development in the developing fetus, based on findings in juvenile animal studies corresponding to the second and third trimester of human pregnancy.
Breastfeeding
- Invokamet is contraindicated during breastfeeding.
- Metformin passes into human breast milk; it is not known whether canagliflozin does, but animal studies show it is excreted into milk.
Geriatrics
- Patients 65 years and older had more adverse effects related to reduced blood volume, such as low blood pressure, dizziness on standing, fainting, and dehydration, particularly with the higher canagliflozin dose and in those over 75.
- Blood sugar improvement with canagliflozin is somewhat smaller in older patients compared with younger patients.
- Kidney function should be checked regularly in older adults, and Invokamet should be used with caution as age increases because of the greater likelihood of reduced kidney function.
Pediatrics
- Health Canada has not authorized Invokamet for use in patients younger than 18 years, as safety and effectiveness have not been established in this age group.
Dosage & Administration
- Invokamet is taken by mouth twice daily with meals, swallowed whole, individualized based on effectiveness and tolerability, up to a maximum of 150 mg canagliflozin/1000 mg metformin twice daily.
- Dose escalation should be gradual to reduce metformin-related gastrointestinal side effects.
- Patients tolerating 50 mg canagliflozin twice daily with adequate kidney function (eGFR 60 mL/min/1.73m2 or higher) who need tighter blood sugar control can have their dose increased to 150 mg canagliflozin twice daily.
- No dose adjustment is needed for mild kidney impairment; canagliflozin should be limited to 100 mg total daily dose once eGFR falls below 60 mL/min/1.73m2, and metformin should be capped at 1000 mg daily once eGFR falls between 30 and 45 mL/min/1.73m2.
- Invokamet is contraindicated and must be stopped once eGFR falls below 30 mL/min/1.73m2.
- If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next dose, in which case the missed dose should be skipped.
- Treatment should be stopped for at least 3 days before major surgery or procedures involving prolonged fasting, and only restarted once the patient is stable and eating normally again.
Overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- Single doses of canagliflozin up to 1600 mg were generally well tolerated in healthy subjects in clinical studies.
- Canagliflozin is only negligibly removed by hemodialysis and is not expected to be removed by peritoneal dialysis.
- Metformin overdose, including ingestion of very large amounts, can cause more intense versions of typical metformin side effects such as stomach discomfort, nausea, vomiting, diarrhea, drowsiness, weakness, dizziness, and headache, and can lead to lactic acidosis.
- Metformin is removable by hemodialysis, which may be useful if metformin overdose is suspected and lactic acidosis develops.
- General supportive measures, removal of unabsorbed drug from the stomach, and clinical monitoring should be used in the event of overdose.
Common side effects
- Yeast infections of the genitals (vulvovaginal candidiasis in women, balanitis in men) may occur.
- Urinary tract infection may occur.
- Increased urination or urinary frequency may occur.
- Nausea, vomiting, or diarrhea may occur.
- Bloating, gas, or loss of appetite may occur.
- A metallic taste in the mouth may occur.
- Thirst may occur.
- Constipation may occur.
Serious side effects
Serious side effects require immediate discussion with the prescriber or emergency care.
- Lactic acidosis, a rare but life-threatening buildup of lactic acid in the blood, can occur with metformin accumulation.
- Diabetic ketoacidosis, including cases with near-normal blood sugar levels, can occur and requires urgent hospitalization.
- Serious dehydration and low blood volume can cause fainting, very low blood pressure, or kidney injury.
- Serious urinary tract infections, including infections that spread to the kidney or bloodstream, may occur.
- Fournier's gangrene, a rare but life-threatening flesh-eating infection of the genital and perineal area, has been reported.
- An increased risk of toe, foot, or leg amputation has been observed with canagliflozin, particularly in patients with prior amputation, poor circulation, nerve damage, or foot ulcers.
- Bone fractures have been reported with canagliflozin use.
- Low blood sugar (hypoglycemia) can occur, especially when Invokamet is combined with insulin or a sulfonylurea.
- Low vitamin B12 levels, sometimes leading to anemia, can develop with long-term metformin use.
- Serious allergic reactions, including anaphylaxis and swelling of the face or throat (angioedema), have been reported.
- Rare cases of severe kidney injury, sometimes requiring hospitalization, have occurred.
- Seek urgent medical attention for unusual tiredness, rapid breathing, muscle pain, stomach pain with nausea and vomiting, or feeling unusually cold, as these may signal lactic acidosis.
Use with caution
- Use with caution in patients with a history of low blood volume, low blood pressure, or who take diuretics, especially loop diuretics, because of the increased risk of dehydration and its complications.
- Use with caution in patients with a history of genital yeast infections or urinary tract infections.
- Use with caution in patients with a history of amputation, peripheral vascular disease, neuropathy, or foot ulcers because of the amputation risk associated with canagliflozin.
- Use with caution in patients with reduced kidney function, and adjust the dose according to kidney function.
- Use with caution in patients 80 years of age or older; Invokamet should not be started in this group unless kidney function has been confirmed to be normal.
- Use with caution in patients with congestive heart failure, particularly unstable or acute heart failure, because of the increased risk of lactic acidosis.
- Use with caution in patients undergoing surgery, imaging with iodinated contrast dye, or any condition causing dehydration, infection, or reduced oxygen delivery to tissues.
- Use with caution in patients with elevated LDL cholesterol, since canagliflozin can raise LDL levels.
Contraindications
- Contraindicated in patients with known hypersensitivity to canagliflozin, metformin, or any ingredient in the formulation.
- Contraindicated in patients with severe kidney impairment, end-stage kidney disease, patients on dialysis, or when kidney function is unknown.
- Contraindicated in acute or chronic metabolic acidosis, including diabetic ketoacidosis, or a history of ketoacidosis or lactic acidosis.
- Contraindicated in unstable or insulin-dependent (type 1) diabetes.
- Contraindicated with excessive alcohol intake, whether acute or chronic.
- Contraindicated in patients with severe liver disease or clinical evidence of liver disease.
- Contraindicated in cardiovascular collapse or conditions associated with low blood oxygen, such as severe heart or lung failure.
- Contraindicated during severe infection, trauma, surgery, or the recovery period after these events.
- Contraindicated in severe dehydration or shock.
- Contraindicated during pregnancy and breastfeeding.
- Contraindicated around the time of receiving iodinated contrast dye for imaging studies.
Drug interactions
- Insulin and insulin-releasing medications such as sulfonylureas can have an additive blood-sugar-lowering effect with Invokamet, increasing the risk of hypoglycemia; a lower dose of these medications may be needed.
- Drugs that induce UGT enzymes, such as rifampin, phenytoin, carbamazepine, ritonavir, and St. John's wort, can lower canagliflozin blood levels and may require a canagliflozin dose increase.
- Lithium levels can be reduced by Invokamet through increased kidney elimination of lithium, so lithium levels should be monitored more closely.
- Combining Invokamet with digoxin increases digoxin blood levels, so patients on digoxin should be monitored appropriately.
- Cationic drugs eliminated by the kidney, such as cimetidine, can raise metformin blood levels and may require dose adjustment or closer monitoring.
- Furosemide and nifedipine can increase metformin blood levels through pharmacokinetic interactions.
- Corticosteroids, thiazide diuretics, phenothiazines, thyroid hormones, estrogens, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, isoniazid, and beta-2 agonists can raise blood sugar and reduce the effectiveness of Invokamet.
- Loop diuretics increase the risk of low blood volume and are not recommended for use with Invokamet.
- Excessive alcohol intake increases the risk of lactic acidosis when combined with metformin.
Food interactions
- Invokamet must be taken with food; taking each dose with a meal helps reduce the gastrointestinal side effects associated with the metformin component.
Time of administration
- Invokamet is taken twice a day with meals, at approximately the same times each day, to minimize stomach upset.
Storage
- Store Invokamet tablets at room temperature, between 15°C and 30°C.
- Do not dispose of unused or expired tablets in household trash or wastewater; ask a pharmacist about proper disposal.
Patient take-away
- Invokamet combines two medicines that work together to lower blood sugar in type 2 diabetes and must be taken exactly as prescribed, with meals.
- Watch for signs of dehydration, genital or urinary infection, and unusual tiredness or stomach pain, and tell your healthcare provider promptly if these occur.
- Invokamet must not be used during pregnancy or while breastfeeding; tell your healthcare provider right away if you become pregnant.